#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Cutaneous squamous cell carcinoma ( cSCC ) is the second most common type of cancer with an annual incidence of over one million globally .
2-1	16-25	Cutaneous	abstract[3]	new[3]	coref	2-9[5_3]
2-2	26-34	squamous	abstract[3]	new[3]	_	_
2-3	35-39	cell	place|abstract[3]	new|new[3]	coref	5-7
2-4	40-49	carcinoma	abstract[3]	new[3]	_	_
2-5	50-51	(	_	_	_	_
2-6	52-56	cSCC	substance	new	coref	3-31
2-7	57-58	)	_	_	_	_
2-8	59-61	is	_	_	_	_
2-9	62-65	the	abstract[5]	giv[5]	_	_
2-10	66-72	second	abstract[5]	giv[5]	_	_
2-11	73-77	most	abstract[5]	giv[5]	_	_
2-12	78-84	common	abstract[5]	giv[5]	_	_
2-13	85-89	type	abstract[5]	giv[5]	_	_
2-14	90-92	of	abstract[5]	giv[5]	_	_
2-15	93-99	cancer	abstract[5]|abstract	giv[5]|new	coref	8-17
2-16	100-104	with	abstract[5]	giv[5]	_	_
2-17	105-107	an	abstract[5]|abstract[7]	giv[5]|new[7]	_	_
2-18	108-114	annual	abstract[5]|abstract[7]	giv[5]|new[7]	_	_
2-19	115-124	incidence	abstract[5]|abstract[7]	giv[5]|new[7]	_	_
2-20	125-127	of	abstract[5]|abstract[7]	giv[5]|new[7]	_	_
2-21	128-132	over	abstract[5]|abstract[7]|abstract[8]	giv[5]|new[7]|new[8]	_	_
2-22	133-136	one	abstract[5]|abstract[7]|abstract[8]	giv[5]|new[7]|new[8]	_	_
2-23	137-144	million	abstract[5]|abstract[7]|abstract[8]	giv[5]|new[7]|new[8]	_	_
2-24	145-153	globally	abstract[5]|abstract[7]	giv[5]|new[7]	_	_
2-25	154-155	.	_	_	_	_

#Text=Chronic ultraviolet ( UV ) exposure was suggested to be responsible for DNA damage of normal keratinocytes in the epidermis , which leads to the development of skin cancers including cSCC .
3-1	156-163	Chronic	abstract[11]	new[11]	_	_
3-2	164-175	ultraviolet	abstract|abstract[11]	new|new[11]	_	_
3-3	176-177	(	abstract[11]	new[11]	_	_
3-4	178-180	UV	abstract|abstract[11]	new|new[11]	_	_
3-5	181-182	)	abstract[11]	new[11]	_	_
3-6	183-191	exposure	abstract[11]	new[11]	_	_
3-7	192-195	was	_	_	_	_
3-8	196-205	suggested	_	_	_	_
3-9	206-208	to	_	_	_	_
3-10	209-211	be	_	_	_	_
3-11	212-223	responsible	_	_	_	_
3-12	224-227	for	_	_	_	_
3-13	228-231	DNA	substance|event[13]	new|new[13]	_	_
3-14	232-238	damage	event[13]	new[13]	_	_
3-15	239-241	of	event[13]	new[13]	_	_
3-16	242-248	normal	event[13]|substance[14]	new[13]|new[14]	_	_
3-17	249-262	keratinocytes	event[13]|substance[14]	new[13]|new[14]	_	_
3-18	263-265	in	event[13]|substance[14]	new[13]|new[14]	_	_
3-19	266-269	the	event[13]|substance[14]|abstract[15]	new[13]|new[14]|new[15]	_	_
3-20	270-279	epidermis	event[13]|substance[14]|abstract[15]	new[13]|new[14]|new[15]	_	_
3-21	280-281	,	event[13]	new[13]	_	_
3-22	282-287	which	event[13]	new[13]	_	_
3-23	288-293	leads	event[13]	new[13]	_	_
3-24	294-296	to	event[13]	new[13]	_	_
3-25	297-300	the	event[13]|event[16]	new[13]|new[16]	_	_
3-26	301-312	development	event[13]|event[16]	new[13]|new[16]	_	_
3-27	313-315	of	event[13]|event[16]	new[13]|new[16]	_	_
3-28	316-320	skin	event[13]|event[16]|object|abstract[18]	new[13]|new[16]|new|new[18]	_	_
3-29	321-328	cancers	event[13]|event[16]|abstract[18]	new[13]|new[16]|new[18]	_	_
3-30	329-338	including	event[13]|event[16]|abstract[18]	new[13]|new[16]|new[18]	_	_
3-31	339-343	cSCC	event[13]|event[16]|abstract[18]|substance	new[13]|new[16]|new[18]|giv	coref	19-20
3-32	344-345	.	_	_	_	_

#Text=However , the detailed underlying molecular mechanisms for this transition still need to be fully elucidated .
4-1	346-353	However	_	_	_	_
4-2	354-355	,	_	_	_	_
4-3	356-359	the	abstract[20]	new[20]	coref	8-3[51_20]
4-4	360-368	detailed	abstract[20]	new[20]	_	_
4-5	369-379	underlying	abstract[20]	new[20]	_	_
4-6	380-389	molecular	abstract[20]	new[20]	_	_
4-7	390-400	mechanisms	abstract[20]	new[20]	_	_
4-8	401-404	for	abstract[20]	new[20]	_	_
4-9	405-409	this	abstract[20]|event[21]	new[20]|new[21]	_	_
4-10	410-420	transition	abstract[20]|event[21]	new[20]|new[21]	_	_
4-11	421-426	still	_	_	_	_
4-12	427-431	need	_	_	_	_
4-13	432-434	to	_	_	_	_
4-14	435-437	be	_	_	_	_
4-15	438-443	fully	_	_	_	_
4-16	444-454	elucidated	_	_	_	_
4-17	455-456	.	_	_	_	_

#Text=Apoptosis is one type of programmed cell death , which is initiated by intrinsic or extrinsic signals and finely-tuned by many factors including BCL-2 family proteins .
5-1	457-466	Apoptosis	abstract	new	coref	5-3[23_0]
5-2	467-469	is	_	_	_	_
5-3	470-473	one	abstract[23]	giv[23]	coref	6-24[0_23]
5-4	474-478	type	abstract[23]	giv[23]	_	_
5-5	479-481	of	abstract[23]	giv[23]	_	_
5-6	482-492	programmed	abstract[23]|event[25]	giv[23]|new[25]	coref	7-3[42_25]
5-7	493-497	cell	abstract[23]|place|event[25]	giv[23]|giv|new[25]	coref	7-3
5-8	498-503	death	abstract[23]|event[25]	giv[23]|new[25]	_	_
5-9	504-505	,	abstract[23]|event[25]	giv[23]|new[25]	_	_
5-10	506-511	which	abstract[23]|event[25]	giv[23]|new[25]	_	_
5-11	512-514	is	abstract[23]|event[25]	giv[23]|new[25]	_	_
5-12	515-524	initiated	abstract[23]|event[25]	giv[23]|new[25]	_	_
5-13	525-527	by	abstract[23]|event[25]	giv[23]|new[25]	_	_
5-14	528-537	intrinsic	abstract[23]|event[25]|abstract[26]	giv[23]|new[25]|new[26]	_	_
5-15	538-540	or	abstract[23]|event[25]|abstract[26]	giv[23]|new[25]|new[26]	_	_
5-16	541-550	extrinsic	abstract[23]|event[25]|abstract[26]	giv[23]|new[25]|new[26]	_	_
5-17	551-558	signals	abstract[23]|event[25]|abstract[26]	giv[23]|new[25]|new[26]	_	_
5-18	559-562	and	abstract[23]|event[25]	giv[23]|new[25]	_	_
5-19	563-575	finely-tuned	abstract[23]|event[25]	giv[23]|new[25]	_	_
5-20	576-578	by	_	_	_	_
5-21	579-583	many	abstract[27]	new[27]	coref	17-4[142_27]
5-22	584-591	factors	abstract[27]	new[27]	_	_
5-23	592-601	including	abstract[27]	new[27]	_	_
5-24	602-607	BCL-2	abstract[27]|abstract|substance[30]	new[27]|new|new[30]	coref|coref	6-1|6-6[36_30]
5-25	608-614	family	abstract[27]|abstract|substance[30]	new[27]|new|new[30]	coref	6-2
5-26	615-623	proteins	abstract[27]|substance[30]	new[27]|new[30]	_	_
5-27	624-625	.	_	_	_	_

#Text=BCL-2 family members , including both anti-apoptotic and pro-apoptotic BCL-2 family proteins , govern mitochondrial outer membrane permeabilization ( MOMP ) to regulate apoptosis .
6-1	626-631	BCL-2	abstract|person[33]	giv|new[33]	coref|coref	6-10|9-45[73_33]
6-2	632-638	family	abstract|person[33]	giv|new[33]	coref	6-11
6-3	639-646	members	person[33]	new[33]	_	_
6-4	647-648	,	person[33]	new[33]	_	_
6-5	649-658	including	person[33]	new[33]	_	_
6-6	659-663	both	person[33]|substance[36]	new[33]|giv[36]	coref	13-10[99_36]
6-7	664-678	anti-apoptotic	person[33]|substance[36]	new[33]|giv[36]	_	_
6-8	679-682	and	person[33]|substance[36]	new[33]|giv[36]	_	_
6-9	683-696	pro-apoptotic	person[33]|substance[36]	new[33]|giv[36]	_	_
6-10	697-702	BCL-2	person[33]|abstract|substance[36]	new[33]|giv|giv[36]	coref	9-1[57_0]
6-11	703-709	family	person[33]|abstract|substance[36]	new[33]|giv|giv[36]	coref	9-49[75_0]
6-12	710-718	proteins	person[33]|substance[36]	new[33]|giv[36]	_	_
6-13	719-720	,	_	_	_	_
6-14	721-727	govern	_	_	_	_
6-15	728-741	mitochondrial	abstract[38]	new[38]	appos	6-20[0_38]
6-16	742-747	outer	object[37]|abstract[38]	new[37]|new[38]	coref	16-34[0_37]
6-17	748-756	membrane	object[37]|abstract[38]	new[37]|new[38]	_	_
6-18	757-773	permeabilization	abstract[38]	new[38]	_	_
6-19	774-775	(	_	_	_	_
6-20	776-780	MOMP	abstract	giv	coref	7-8
6-21	781-782	)	_	_	_	_
6-22	783-785	to	_	_	_	_
6-23	786-794	regulate	_	_	_	_
6-24	795-804	apoptosis	abstract	giv	coref	8-7
6-25	805-806	.	_	_	_	_

#Text=When apoptotic cell death program starts , MOMP releases cytochrome c to cytosol and activates caspase-family proteases for initiating apoptotic events .
7-1	807-811	When	_	_	_	_
7-2	812-821	apoptotic	event[43]	new[43]	_	_
7-3	822-826	cell	place|event[42]|event[43]	giv|giv[42]|new[43]	coref|coref	10-20[0_42]|14-11
7-4	827-832	death	event[42]|event[43]	giv[42]|new[43]	_	_
7-5	833-840	program	event[43]	new[43]	_	_
7-6	841-847	starts	_	_	_	_
7-7	848-849	,	_	_	_	_
7-8	850-854	MOMP	abstract	giv	_	_
7-9	855-863	releases	_	_	_	_
7-10	864-874	cytochrome	substance[45]	new[45]	_	_
7-11	875-876	c	substance[45]	new[45]	_	_
7-12	877-879	to	_	_	_	_
7-13	880-887	cytosol	person	new	_	_
7-14	888-891	and	_	_	_	_
7-15	892-901	activates	_	_	_	_
7-16	902-916	caspase-family	abstract|abstract[48]	new|new[48]	_	_
7-17	917-926	proteases	abstract[48]	new[48]	_	_
7-18	927-930	for	_	_	_	_
7-19	931-941	initiating	_	_	_	_
7-20	942-951	apoptotic	event[49]	new[49]	_	_
7-21	952-958	events	event[49]	new[49]	_	_
7-22	959-960	.	_	_	_	_

#Text=Tumors develop effective mechanisms to resist apoptosis and thus become one of the hallmark features of cancer .
8-1	961-967	Tumors	abstract	new	_	_
8-2	968-975	develop	_	_	_	_
8-3	976-985	effective	abstract[51]	giv[51]	coref	21-3[174_51]
8-4	986-996	mechanisms	abstract[51]	giv[51]	_	_
8-5	997-999	to	abstract[51]	giv[51]	_	_
8-6	1000-1006	resist	abstract[51]	giv[51]	_	_
8-7	1007-1016	apoptosis	abstract[51]|abstract	giv[51]|giv	coref	14-8[108_0]
8-8	1017-1020	and	_	_	_	_
8-9	1021-1025	thus	_	_	_	_
8-10	1026-1032	become	_	_	_	_
8-11	1033-1036	one	abstract[53]	new[53]	_	_
8-12	1037-1039	of	abstract[53]	new[53]	_	_
8-13	1040-1043	the	abstract[53]|abstract[54]	new[53]|new[54]	ana	9-38[0_54]
8-14	1044-1052	hallmark	abstract[53]|abstract[54]	new[53]|new[54]	_	_
8-15	1053-1061	features	abstract[53]|abstract[54]	new[53]|new[54]	_	_
8-16	1062-1064	of	abstract[53]|abstract[54]	new[53]|new[54]	_	_
8-17	1065-1071	cancer	abstract[53]|abstract[54]|abstract	new[53]|new[54]|giv	coref	10-17
8-18	1072-1073	.	_	_	_	_

#Text=The lead member BCL-2 and its homologue BCL-XL ( BCL2L1 ) are featured by the presence of four conserved BH domains , three of which , BH1 , BH2 , and BH3 domains , are responsible for their antiapoptotic role mainly by interactions with other proapoptotic members of the BCL-2 family .
9-1	1074-1077	The	animal[56]|abstract[57]	new[56]|giv[57]	ana	9-6[0_57]
9-2	1078-1082	lead	animal[56]|abstract[57]	new[56]|giv[57]	_	_
9-3	1083-1089	member	animal[56]|abstract[57]	new[56]|giv[57]	_	_
9-4	1090-1095	BCL-2	abstract[57]	giv[57]	_	_
9-5	1096-1099	and	_	_	_	_
9-6	1100-1103	its	abstract|abstract[59]	giv|new[59]	coref	10-6
9-7	1104-1113	homologue	abstract[59]	new[59]	_	_
9-8	1114-1120	BCL-XL	abstract	new	appos	9-10
9-9	1121-1122	(	_	_	_	_
9-10	1123-1129	BCL2L1	abstract	giv	coref	23-6
9-11	1130-1131	)	_	_	_	_
9-12	1132-1135	are	_	_	_	_
9-13	1136-1144	featured	_	_	_	_
9-14	1145-1147	by	_	_	_	_
9-15	1148-1151	the	abstract[62]	new[62]	_	_
9-16	1152-1160	presence	abstract[62]	new[62]	_	_
9-17	1161-1163	of	abstract[62]	new[62]	_	_
9-18	1164-1168	four	abstract[62]|abstract[64]	new[62]|new[64]	_	_
9-19	1169-1178	conserved	abstract[62]|abstract[64]	new[62]|new[64]	_	_
9-20	1179-1181	BH	abstract[62]|person|abstract[64]	new[62]|new|new[64]	_	_
9-21	1182-1189	domains	abstract[62]|abstract[64]	new[62]|new[64]	_	_
9-22	1190-1191	,	abstract[62]|abstract[64]	new[62]|new[64]	_	_
9-23	1192-1197	three	abstract[62]|abstract[64]|abstract[65]	new[62]|new[64]|new[65]	appos	9-27[0_65]
9-24	1198-1200	of	abstract[62]|abstract[64]|abstract[65]	new[62]|new[64]|new[65]	_	_
9-25	1201-1206	which	abstract[62]|abstract[64]|abstract[65]	new[62]|new[64]|new[65]	_	_
9-26	1207-1208	,	abstract[62]|abstract[64]	new[62]|new[64]	_	_
9-27	1209-1212	BH1	abstract[62]|abstract[64]|abstract	new[62]|new[64]|giv	appos	9-29
9-28	1213-1214	,	abstract[62]|abstract[64]	new[62]|new[64]	_	_
9-29	1215-1218	BH2	abstract[62]|abstract[64]|abstract	new[62]|new[64]|giv	appos	9-32
9-30	1219-1220	,	abstract[62]|abstract[64]	new[62]|new[64]	_	_
9-31	1221-1224	and	abstract[62]|abstract[64]	new[62]|new[64]	_	_
9-32	1225-1228	BH3	abstract[62]|abstract[64]|abstract	new[62]|new[64]|giv	appos	9-33
9-33	1229-1236	domains	abstract[62]|abstract[64]|abstract	new[62]|new[64]|giv	coref	10-13
9-34	1237-1238	,	abstract[62]|abstract[64]	new[62]|new[64]	_	_
9-35	1239-1242	are	abstract[62]|abstract[64]	new[62]|new[64]	_	_
9-36	1243-1254	responsible	abstract[62]|abstract[64]	new[62]|new[64]	_	_
9-37	1255-1258	for	abstract[62]|abstract[64]	new[62]|new[64]	_	_
9-38	1259-1264	their	abstract[62]|abstract[64]|abstract|abstract[71]	new[62]|new[64]|giv|new[71]	_	_
9-39	1265-1278	antiapoptotic	abstract[62]|abstract[64]|abstract[71]	new[62]|new[64]|new[71]	_	_
9-40	1279-1283	role	abstract[62]|abstract[64]|abstract[71]	new[62]|new[64]|new[71]	_	_
9-41	1284-1290	mainly	abstract[62]|abstract[64]|event[72]	new[62]|new[64]|new[72]	_	_
9-42	1291-1293	by	abstract[62]|abstract[64]|event[72]	new[62]|new[64]|new[72]	_	_
9-43	1294-1306	interactions	abstract[62]|abstract[64]|event[72]	new[62]|new[64]|new[72]	_	_
9-44	1307-1311	with	abstract[62]|abstract[64]|event[72]	new[62]|new[64]|new[72]	_	_
9-45	1312-1317	other	abstract[62]|abstract[64]|event[72]|person[73]	new[62]|new[64]|new[72]|giv[73]	coref	10-5[78_73]
9-46	1318-1330	proapoptotic	abstract[62]|abstract[64]|event[72]|person[73]	new[62]|new[64]|new[72]|giv[73]	_	_
9-47	1331-1338	members	abstract[62]|abstract[64]|event[72]|person[73]	new[62]|new[64]|new[72]|giv[73]	_	_
9-48	1339-1341	of	abstract[62]|abstract[64]|event[72]|person[73]	new[62]|new[64]|new[72]|giv[73]	_	_
9-49	1342-1345	the	abstract[62]|abstract[64]|event[72]|person[73]|abstract[75]	new[62]|new[64]|new[72]|giv[73]|giv[75]	coref	12-10[0_75]
9-50	1346-1351	BCL-2	abstract[62]|abstract[64]|event[72]|person[73]|person|abstract[75]	new[62]|new[64]|new[72]|giv[73]|new|giv[75]	_	_
9-51	1352-1358	family	abstract[62]|abstract[64]|event[72]|person[73]|abstract[75]	new[62]|new[64]|new[72]|giv[73]|giv[75]	_	_
9-52	1359-1360	.	_	_	_	_

#Text=Inhibiting the activities of anti-apoptotic BCL-2 members by drugs or neutralizing by BH3 peptides to prime cancer cells to death has been regarded as effective therapeutic modalities .
10-1	1361-1371	Inhibiting	_	_	_	_
10-2	1372-1375	the	event[76]	new[76]	_	_
10-3	1376-1386	activities	event[76]	new[76]	_	_
10-4	1387-1389	of	event[76]	new[76]	_	_
10-5	1390-1404	anti-apoptotic	event[76]|person[78]	new[76]|giv[78]	coref	11-13[90_78]
10-6	1405-1410	BCL-2	event[76]|abstract|person[78]	new[76]|giv|giv[78]	coref	11-14
10-7	1411-1418	members	event[76]|person[78]	new[76]|giv[78]	_	_
10-8	1419-1421	by	_	_	_	_
10-9	1422-1427	drugs	substance	new	_	_
10-10	1428-1430	or	_	_	_	_
10-11	1431-1443	neutralizing	_	_	_	_
10-12	1444-1446	by	_	_	_	_
10-13	1447-1450	BH3	abstract|place[81]	giv|new[81]	coref	15-1[113_81]
10-14	1451-1459	peptides	place[81]	new[81]	_	_
10-15	1460-1462	to	_	_	_	_
10-16	1463-1468	prime	_	_	_	_
10-17	1469-1475	cancer	abstract|animal[83]	giv|new[83]	coref|coref	11-17|15-22[121_83]
10-18	1476-1481	cells	animal[83]	new[83]	_	_
10-19	1482-1484	to	_	_	_	_
10-20	1485-1490	death	event	giv	coref	14-8[110_0]
10-21	1491-1494	has	_	_	_	_
10-22	1495-1499	been	_	_	_	_
10-23	1500-1508	regarded	_	_	_	_
10-24	1509-1511	as	_	_	_	_
10-25	1512-1521	effective	abstract[85]	new[85]	_	_
10-26	1522-1533	therapeutic	abstract[85]	new[85]	_	_
10-27	1534-1544	modalities	abstract[85]	new[85]	_	_
10-28	1545-1546	.	_	_	_	_

#Text=In another way , transcriptionally or post-transcriptionally repressing the expression levels of anti-apoptotic BCL-2 members in cancer is also promising .
11-1	1547-1549	In	_	_	_	_
11-2	1550-1557	another	abstract[86]	new[86]	_	_
11-3	1558-1561	way	abstract[86]	new[86]	_	_
11-4	1562-1563	,	_	_	_	_
11-5	1564-1581	transcriptionally	_	_	_	_
11-6	1582-1584	or	_	_	_	_
11-7	1585-1607	post-transcriptionally	_	_	_	_
11-8	1608-1618	repressing	_	_	_	_
11-9	1619-1622	the	abstract[88]	new[88]	_	_
11-10	1623-1633	expression	abstract|abstract[88]	new|new[88]	coref	12-6[93_0]
11-11	1634-1640	levels	abstract[88]	new[88]	_	_
11-12	1641-1643	of	abstract[88]	new[88]	_	_
11-13	1644-1658	anti-apoptotic	abstract[88]|person[90]	new[88]|giv[90]	coref	12-9[96_90]
11-14	1659-1664	BCL-2	abstract[88]|abstract|person[90]	new[88]|giv|giv[90]	coref	12-9
11-15	1665-1672	members	abstract[88]|person[90]	new[88]|giv[90]	_	_
11-16	1673-1675	in	_	_	_	_
11-17	1676-1682	cancer	abstract	giv	_	_
11-18	1683-1685	is	_	_	_	_
11-19	1686-1690	also	_	_	_	_
11-20	1691-1700	promising	_	_	_	_
11-21	1701-1702	.	_	_	_	_

#Text=However , the mechanism regulating the expression of BCL-2 family members still remain unclear .
12-1	1703-1710	However	_	_	_	_
12-2	1711-1712	,	_	_	_	_
12-3	1713-1716	the	abstract[92]	new[92]	_	_
12-4	1717-1726	mechanism	abstract[92]	new[92]	_	_
12-5	1727-1737	regulating	abstract[92]	new[92]	_	_
12-6	1738-1741	the	abstract[92]|abstract[93]	new[92]|giv[93]	_	_
12-7	1742-1752	expression	abstract[92]|abstract[93]	new[92]|giv[93]	_	_
12-8	1753-1755	of	abstract[92]|abstract[93]	new[92]|giv[93]	_	_
12-9	1756-1761	BCL-2	abstract[92]|abstract[93]|abstract|person[96]	new[92]|giv[93]|giv|giv[96]	_	_
12-10	1762-1768	family	abstract[92]|abstract[93]|abstract|person[96]	new[92]|giv[93]|giv|giv[96]	_	_
12-11	1769-1776	members	abstract[92]|abstract[93]|person[96]	new[92]|giv[93]|giv[96]	_	_
12-12	1777-1782	still	_	_	_	_
12-13	1783-1789	remain	_	_	_	_
12-14	1790-1797	unclear	_	_	_	_
12-15	1798-1799	.	_	_	_	_

#Text=Autophagy is an evolutionarily-conserved catabolic process , during which “ useless ” proteins and damaged organelles are sequestrated into autophagosomes and fused with lysosomes to form autolysosomes for bulk degradation of embedded components .
13-1	1800-1809	Autophagy	event	new	coref	13-3[98_0]
13-2	1810-1812	is	_	_	_	_
13-3	1813-1815	an	event[98]	giv[98]	coref	14-2[107_98]
13-4	1816-1840	evolutionarily-conserved	event[98]	giv[98]	_	_
13-5	1841-1850	catabolic	event[98]	giv[98]	_	_
13-6	1851-1858	process	event[98]	giv[98]	_	_
13-7	1859-1860	,	event[98]	giv[98]	_	_
13-8	1861-1867	during	event[98]	giv[98]	_	_
13-9	1868-1873	which	event[98]	giv[98]	_	_
13-10	1874-1875	“	event[98]|substance[99]|substance[100]	giv[98]|giv[99]|giv[100]	coref	13-10[100_99]
13-11	1876-1883	useless	event[98]|substance[99]|substance[100]	giv[98]|giv[99]|giv[100]	_	_
13-12	1884-1885	”	event[98]|substance[99]|substance[100]	giv[98]|giv[99]|giv[100]	_	_
13-13	1886-1894	proteins	event[98]|substance[99]|substance[100]	giv[98]|giv[99]|giv[100]	_	_
13-14	1895-1898	and	event[98]|substance[100]	giv[98]|giv[100]	_	_
13-15	1899-1906	damaged	event[98]|substance[100]|object[101]	giv[98]|giv[100]|new[101]	_	_
13-16	1907-1917	organelles	event[98]|substance[100]|object[101]	giv[98]|giv[100]|new[101]	_	_
13-17	1918-1921	are	event[98]	giv[98]	_	_
13-18	1922-1934	sequestrated	event[98]	giv[98]	_	_
13-19	1935-1939	into	event[98]	giv[98]	_	_
13-20	1940-1954	autophagosomes	event[98]|object	giv[98]|new	_	_
13-21	1955-1958	and	event[98]	giv[98]	_	_
13-22	1959-1964	fused	event[98]	giv[98]	_	_
13-23	1965-1969	with	_	_	_	_
13-24	1970-1979	lysosomes	substance	new	_	_
13-25	1980-1982	to	_	_	_	_
13-26	1983-1987	form	_	_	_	_
13-27	1988-2001	autolysosomes	organization	new	_	_
13-28	2002-2005	for	_	_	_	_
13-29	2006-2010	bulk	event[105]	new[105]	_	_
13-30	2011-2022	degradation	event[105]	new[105]	_	_
13-31	2023-2025	of	event[105]	new[105]	_	_
13-32	2026-2034	embedded	event[105]|object[106]	new[105]|new[106]	coref	16-41[139_106]
13-33	2035-2045	components	event[105]|object[106]	new[105]|new[106]	_	_
13-34	2046-2047	.	_	_	_	_

#Text=Except the dysregulated autophagic process defined as type II programmed cell death , autophagy is generally regarded as protective cellular process .
14-1	2048-2054	Except	_	_	_	_
14-2	2055-2058	the	event[107]	giv[107]	coref	14-14[0_107]
14-3	2059-2071	dysregulated	event[107]	giv[107]	_	_
14-4	2072-2082	autophagic	event[107]	giv[107]	_	_
14-5	2083-2090	process	event[107]	giv[107]	_	_
14-6	2091-2098	defined	event[107]	giv[107]	_	_
14-7	2099-2101	as	event[107]	giv[107]	_	_
14-8	2102-2106	type	event[107]|abstract[108]|event[110]	giv[107]|giv[108]|giv[110]	coref	20-14[171_108]
14-9	2107-2109	II	event[107]|abstract[108]|event[110]	giv[107]|giv[108]|giv[110]	_	_
14-10	2110-2120	programmed	event[107]|event[110]	giv[107]|giv[110]	_	_
14-11	2121-2125	cell	event[107]|place|event[110]	giv[107]|giv|giv[110]	_	_
14-12	2126-2131	death	event[107]|event[110]	giv[107]|giv[110]	_	_
14-13	2132-2133	,	_	_	_	_
14-14	2134-2143	autophagy	event	giv	coref	14-19[112_0]
14-15	2144-2146	is	_	_	_	_
14-16	2147-2156	generally	_	_	_	_
14-17	2157-2165	regarded	_	_	_	_
14-18	2166-2168	as	_	_	_	_
14-19	2169-2179	protective	event[112]	giv[112]	coref	16-26[0_112]
14-20	2180-2188	cellular	event[112]	giv[112]	_	_
14-21	2189-2196	process	event[112]	giv[112]	_	_
14-22	2197-2198	.	_	_	_	_

#Text=The recycled peptides , nucleotides and lipids together with the energy are critical to the maintenance of cellular homeostasis and support tumor cells to survive under stressful environment .
15-1	2199-2202	The	place[113]|place[114]	giv[113]|giv[114]	coref	15-1[114_113]
15-2	2203-2211	recycled	place[113]|place[114]	giv[113]|giv[114]	_	_
15-3	2212-2220	peptides	place[113]|place[114]	giv[113]|giv[114]	_	_
15-4	2221-2222	,	place[114]	giv[114]	_	_
15-5	2223-2234	nucleotides	place[114]|substance	giv[114]|new	_	_
15-6	2235-2238	and	place[114]	giv[114]	_	_
15-7	2239-2245	lipids	place[114]|substance[116]	giv[114]|new[116]	_	_
15-8	2246-2254	together	place[114]|substance[116]	giv[114]|new[116]	_	_
15-9	2255-2259	with	place[114]|substance[116]	giv[114]|new[116]	_	_
15-10	2260-2263	the	place[114]|substance[116]|abstract[117]	giv[114]|new[116]|new[117]	_	_
15-11	2264-2270	energy	place[114]|substance[116]|abstract[117]	giv[114]|new[116]|new[117]	_	_
15-12	2271-2274	are	_	_	_	_
15-13	2275-2283	critical	_	_	_	_
15-14	2284-2286	to	_	_	_	_
15-15	2287-2290	the	abstract[118]	new[118]	_	_
15-16	2291-2302	maintenance	abstract[118]	new[118]	_	_
15-17	2303-2305	of	abstract[118]	new[118]	_	_
15-18	2306-2314	cellular	abstract[118]|abstract[119]	new[118]|new[119]	_	_
15-19	2315-2326	homeostasis	abstract[118]|abstract[119]	new[118]|new[119]	_	_
15-20	2327-2330	and	_	_	_	_
15-21	2331-2338	support	_	_	_	_
15-22	2339-2344	tumor	animal|animal[121]	new|giv[121]	coref|coref	19-17|19-23[0_121]
15-23	2345-2350	cells	animal[121]	giv[121]	_	_
15-24	2351-2353	to	_	_	_	_
15-25	2354-2361	survive	_	_	_	_
15-26	2362-2367	under	_	_	_	_
15-27	2368-2377	stressful	abstract[122]	new[122]	_	_
15-28	2378-2389	environment	abstract[122]	new[122]	_	_
15-29	2390-2391	.	_	_	_	_

#Text=Autophagy-related genes ( ATGs ) , including ULK1 ( ATG1 ) , ATG3 , and ATG12 etc. , are involved in the distinct stages of autophagy : initiation , autophagosome nucleation , autophagosome membrane expansion , fusion with lysosome and the intravesicular components degradation .
16-1	2392-2409	Autophagy-related	abstract[123]	new[123]	appos	16-4[0_123]
16-2	2410-2415	genes	abstract[123]	new[123]	_	_
16-3	2416-2417	(	_	_	_	_
16-4	2418-2422	ATGs	abstract	giv	coref	17-10[144_0]
16-5	2423-2424	)	_	_	_	_
16-6	2425-2426	,	_	_	_	_
16-7	2427-2436	including	_	_	_	_
16-8	2437-2441	ULK1	abstract	new	appos	16-10
16-9	2442-2443	(	_	_	_	_
16-10	2444-2448	ATG1	abstract	giv	coref	23-14
16-11	2449-2450	)	_	_	_	_
16-12	2451-2452	,	_	_	_	_
16-13	2453-2457	ATG3	abstract	new	coref	23-16
16-14	2458-2459	,	_	_	_	_
16-15	2460-2463	and	_	_	_	_
16-16	2464-2469	ATG12	abstract[128]	new[128]	_	_
16-17	2470-2474	etc.	abstract[128]	new[128]	_	_
16-18	2475-2476	,	_	_	_	_
16-19	2477-2480	are	_	_	_	_
16-20	2481-2489	involved	_	_	_	_
16-21	2490-2492	in	_	_	_	_
16-22	2493-2496	the	abstract[129]	new[129]	_	_
16-23	2497-2505	distinct	abstract[129]	new[129]	_	_
16-24	2506-2512	stages	abstract[129]	new[129]	_	_
16-25	2513-2515	of	abstract[129]	new[129]	_	_
16-26	2516-2525	autophagy	abstract[129]|event	new[129]|giv	appos	16-30[133_0]
16-27	2526-2527	:	_	_	_	_
16-28	2528-2538	initiation	event	new	_	_
16-29	2539-2540	,	_	_	_	_
16-30	2541-2554	autophagosome	abstract|event[133]	new|giv[133]	coref|appos	16-33|16-33[136_133]
16-31	2555-2565	nucleation	event[133]	giv[133]	_	_
16-32	2566-2567	,	_	_	_	_
16-33	2568-2581	autophagosome	abstract|event[136]	giv|giv[136]	appos	16-37[137_136]
16-34	2582-2590	membrane	object|event[136]	giv|giv[136]	_	_
16-35	2591-2600	expansion	event[136]	giv[136]	_	_
16-36	2601-2602	,	_	_	_	_
16-37	2603-2609	fusion	event[137]	giv[137]	appos	16-41[140_137]
16-38	2610-2614	with	event[137]	giv[137]	_	_
16-39	2615-2623	lysosome	event[137]|substance	giv[137]|new	_	_
16-40	2624-2627	and	_	_	_	_
16-41	2628-2631	the	object[139]|event[140]	giv[139]|giv[140]	coref	23-23[0_140]
16-42	2632-2646	intravesicular	object[139]|event[140]	giv[139]|giv[140]	_	_
16-43	2647-2657	components	object[139]|event[140]	giv[139]|giv[140]	_	_
16-44	2658-2669	degradation	event[140]	giv[140]	_	_
16-45	2670-2671	.	_	_	_	_

#Text=Signaling pathways or critical factors are involved in regulating ATG genes , including Class III PI3-kinase complex I , mTORC I complex , mTORC II complex and Beclin1 et al. .
17-1	2672-2681	Signaling	abstract[141]	new[141]	_	_
17-2	2682-2690	pathways	abstract[141]	new[141]	_	_
17-3	2691-2693	or	_	_	_	_
17-4	2694-2702	critical	abstract[142]	giv[142]	_	_
17-5	2703-2710	factors	abstract[142]	giv[142]	_	_
17-6	2711-2714	are	_	_	_	_
17-7	2715-2723	involved	_	_	_	_
17-8	2724-2726	in	_	_	_	_
17-9	2727-2737	regulating	_	_	_	_
17-10	2738-2741	ATG	abstract|abstract[144]	new|giv[144]	coref|coref	18-8|18-7[156_144]
17-11	2742-2747	genes	abstract[144]	giv[144]	_	_
17-12	2748-2749	,	_	_	_	_
17-13	2750-2759	including	_	_	_	_
17-14	2760-2765	Class	abstract[145]|abstract[146]|place[147]	new[145]|new[146]|new[147]	_	_
17-15	2766-2769	III	abstract[145]|abstract[146]|place[147]	new[145]|new[146]|new[147]	_	_
17-16	2770-2780	PI3-kinase	abstract[146]|place[147]	new[146]|new[147]	_	_
17-17	2781-2788	complex	place[147]	new[147]	_	_
17-18	2789-2790	I	place[147]	new[147]	_	_
17-19	2791-2792	,	_	_	_	_
17-20	2793-2798	mTORC	abstract	new	coref	17-24
17-21	2799-2800	I	person	new	_	_
17-22	2801-2808	complex	_	_	_	_
17-23	2809-2810	,	_	_	_	_
17-24	2811-2816	mTORC	abstract|abstract[152]	giv|new[152]	_	_
17-25	2817-2819	II	person|abstract[152]	new|new[152]	_	_
17-26	2820-2827	complex	abstract[152]	new[152]	_	_
17-27	2828-2831	and	_	_	_	_
17-28	2832-2839	Beclin1	person	new	_	_
17-29	2840-2842	et	_	_	_	_
17-30	2843-2846	al.	_	_	_	_
17-31	2847-2848	.	_	_	_	_

#Text=However , the transcriptional regulation of the ATG genes is not fully explored .
18-1	2849-2856	However	_	_	_	_
18-2	2857-2858	,	_	_	_	_
18-3	2859-2862	the	abstract[154]	new[154]	_	_
18-4	2863-2878	transcriptional	abstract[154]	new[154]	_	_
18-5	2879-2889	regulation	abstract[154]	new[154]	_	_
18-6	2890-2892	of	abstract[154]	new[154]	_	_
18-7	2893-2896	the	abstract[154]|abstract[156]	new[154]|giv[156]	coref	23-11[190_156]
18-8	2897-2900	ATG	abstract[154]|abstract|abstract[156]	new[154]|giv|giv[156]	coref	23-11
18-9	2901-2906	genes	abstract[154]|abstract[156]	new[154]|giv[156]	_	_
18-10	2907-2909	is	_	_	_	_
18-11	2910-2913	not	_	_	_	_
18-12	2914-2919	fully	_	_	_	_
18-13	2920-2928	explored	_	_	_	_
18-14	2929-2930	.	_	_	_	_

#Text=In our previous study , Homeobox A9 ( HOXA9 ) was significantly downregulated and identified as tumor suppressor in cSCC tumors and cells .
19-1	2931-2933	In	_	_	_	_
19-2	2934-2937	our	person|abstract[158]	acc|new[158]	coref|ana	22-2[177_158]|22-5
19-3	2938-2946	previous	abstract[158]	new[158]	_	_
19-4	2947-2952	study	abstract[158]	new[158]	_	_
19-5	2953-2954	,	_	_	_	_
19-6	2955-2963	Homeobox	abstract	new	appos	19-9
19-7	2964-2966	A9	abstract	new	_	_
19-8	2967-2968	(	_	_	_	_
19-9	2969-2974	HOXA9	abstract	giv	coref	20-1
19-10	2975-2976	)	_	_	_	_
19-11	2977-2980	was	_	_	_	_
19-12	2981-2994	significantly	_	_	_	_
19-13	2995-3008	downregulated	_	_	_	_
19-14	3009-3012	and	_	_	_	_
19-15	3013-3023	identified	_	_	_	_
19-16	3024-3026	as	_	_	_	_
19-17	3027-3032	tumor	animal|abstract[163]	giv|new[163]	coref	24-15
19-18	3033-3043	suppressor	abstract[163]	new[163]	_	_
19-19	3044-3046	in	abstract[163]	new[163]	_	_
19-20	3047-3051	cSCC	abstract[163]|substance|object[165]	new[163]|giv|new[165]	coref	20-16
19-21	3052-3058	tumors	abstract[163]|object[165]	new[163]|new[165]	_	_
19-22	3059-3062	and	abstract[163]	new[163]	_	_
19-23	3063-3068	cells	abstract[163]|animal	new[163]|giv	coref	20-16[173_0]
19-24	3069-3070	.	_	_	_	_

#Text=HOXA9 functions in repressing the proliferation , migration and invasiveness , while promoting apoptosis of cSCC cells .
20-1	3071-3076	HOXA9	abstract	giv	coref	21-7
20-2	3077-3086	functions	_	_	_	_
20-3	3087-3089	in	_	_	_	_
20-4	3090-3100	repressing	_	_	_	_
20-5	3101-3104	the	abstract[168]	new[168]	_	_
20-6	3105-3118	proliferation	abstract[168]	new[168]	_	_
20-7	3119-3120	,	_	_	_	_
20-8	3121-3130	migration	event	new	_	_
20-9	3131-3134	and	_	_	_	_
20-10	3135-3147	invasiveness	event	new	_	_
20-11	3148-3149	,	_	_	_	_
20-12	3150-3155	while	_	_	_	_
20-13	3156-3165	promoting	_	_	_	_
20-14	3166-3175	apoptosis	abstract[171]	giv[171]	coref	21-9[0_171]
20-15	3176-3178	of	abstract[171]	giv[171]	_	_
20-16	3179-3183	cSCC	abstract[171]|substance|animal[173]	giv[171]|giv|giv[173]	coref	23-2
20-17	3184-3189	cells	abstract[171]|animal[173]	giv[171]|giv[173]	_	_
20-18	3190-3191	.	_	_	_	_

#Text=However , the mechanisms about how HOXA9 regulate apoptosis has not been explored and remain to be elucidated .
21-1	3192-3199	However	_	_	_	_
21-2	3200-3201	,	_	_	_	_
21-3	3202-3205	the	abstract[174]	giv[174]	_	_
21-4	3206-3216	mechanisms	abstract[174]	giv[174]	_	_
21-5	3217-3222	about	abstract[174]	giv[174]	_	_
21-6	3223-3226	how	abstract[174]	giv[174]	_	_
21-7	3227-3232	HOXA9	abstract[174]|abstract	giv[174]|giv	coref	22-18
21-8	3233-3241	regulate	abstract[174]	giv[174]	_	_
21-9	3242-3251	apoptosis	abstract[174]|abstract	giv[174]|giv	coref	23-9
21-10	3252-3255	has	_	_	_	_
21-11	3256-3259	not	_	_	_	_
21-12	3260-3264	been	_	_	_	_
21-13	3265-3273	explored	_	_	_	_
21-14	3274-3277	and	_	_	_	_
21-15	3278-3284	remain	_	_	_	_
21-16	3285-3287	to	_	_	_	_
21-17	3288-3290	be	_	_	_	_
21-18	3291-3301	elucidated	_	_	_	_
21-19	3302-3303	.	_	_	_	_

#Text=In this study , we found RELA ( p65 subunit of NF-κB ) is transcriptionally repressed by HOXA9 .
22-1	3304-3306	In	_	_	_	_
22-2	3307-3311	this	abstract[177]	giv[177]	coref	24-1[197_177]
22-3	3312-3317	study	abstract[177]	giv[177]	_	_
22-4	3318-3319	,	_	_	_	_
22-5	3320-3322	we	person	giv	ana	24-1
22-6	3323-3328	found	_	_	_	_
22-7	3329-3333	RELA	abstract	new	appos	22-9[181_0]
22-8	3334-3335	(	_	_	_	_
22-9	3336-3339	p65	abstract|abstract[181]	new|giv[181]	coref	23-4[0_181]
22-10	3340-3347	subunit	abstract[181]	giv[181]	_	_
22-11	3348-3350	of	abstract[181]	giv[181]	_	_
22-12	3351-3356	NF-κB	abstract[181]|substance	giv[181]|new	_	_
22-13	3357-3358	)	_	_	_	_
22-14	3359-3361	is	_	_	_	_
22-15	3362-3379	transcriptionally	_	_	_	_
22-16	3380-3389	repressed	_	_	_	_
22-17	3390-3392	by	_	_	_	_
22-18	3393-3398	HOXA9	abstract	giv	_	_
22-19	3399-3400	.	_	_	_	_

#Text=In cSCC , RELA transactivates BCL-XL to antagonize apoptosis and ATG genes ( ULK1 , ATG3 , and ATG12 ) to promote autophagy .
23-1	3401-3403	In	_	_	_	_
23-2	3404-3408	cSCC	substance	giv	coref	24-18
23-3	3409-3410	,	_	_	_	_
23-4	3411-3415	RELA	abstract	giv	_	_
23-5	3416-3430	transactivates	_	_	_	_
23-6	3431-3437	BCL-XL	abstract	giv	_	_
23-7	3438-3440	to	_	_	_	_
23-8	3441-3451	antagonize	_	_	_	_
23-9	3452-3461	apoptosis	abstract|abstract[188]	giv|new[188]	coref|coref	24-8[200_0]|24-8[201_188]
23-10	3462-3465	and	abstract[188]	new[188]	_	_
23-11	3466-3469	ATG	abstract[188]|abstract|abstract[190]	new[188]|giv|giv[190]	appos	23-14[192_190]
23-12	3470-3475	genes	abstract[188]|abstract[190]	new[188]|giv[190]	_	_
23-13	3476-3477	(	_	_	_	_
23-14	3478-3482	ULK1	abstract|abstract[192]	giv|giv[192]	appos	23-19[0_192]
23-15	3483-3484	,	abstract[192]	giv[192]	_	_
23-16	3485-3489	ATG3	abstract[192]|abstract	giv[192]|giv	_	_
23-17	3490-3491	,	abstract[192]	giv[192]	_	_
23-18	3492-3495	and	abstract[192]	giv[192]	_	_
23-19	3496-3501	ATG12	abstract[192]|abstract	giv[192]|giv	_	_
23-20	3502-3503	)	_	_	_	_
23-21	3504-3506	to	_	_	_	_
23-22	3507-3514	promote	_	_	_	_
23-23	3515-3524	autophagy	event	giv	coref	24-12[202_0]
23-24	3525-3526	.	_	_	_	_

#Text=Our study highlights a HOXA9-NF-κB axis regulates both the apoptosis and autophagy to promote tumor development in cSCC , which may suggest novel intervention targets for cSCC therapy .
24-1	3527-3530	Our	person|abstract[197]	giv|giv[197]	_	_
24-2	3531-3536	study	abstract[197]	giv[197]	_	_
24-3	3537-3547	highlights	_	_	_	_
24-4	3548-3549	a	abstract[199]	new[199]	_	_
24-5	3550-3561	HOXA9-NF-κB	object|abstract[199]	new|new[199]	_	_
24-6	3562-3566	axis	abstract[199]	new[199]	_	_
24-7	3567-3576	regulates	_	_	_	_
24-8	3577-3581	both	abstract[200]|abstract[201]	giv[200]|giv[201]	_	_
24-9	3582-3585	the	abstract[200]|abstract[201]	giv[200]|giv[201]	_	_
24-10	3586-3595	apoptosis	abstract[200]|abstract[201]	giv[200]|giv[201]	_	_
24-11	3596-3599	and	abstract[201]	giv[201]	_	_
24-12	3600-3609	autophagy	abstract[201]|event[202]	giv[201]|giv[202]	_	_
24-13	3610-3612	to	abstract[201]|event[202]	giv[201]|giv[202]	_	_
24-14	3613-3620	promote	abstract[201]|event[202]	giv[201]|giv[202]	_	_
24-15	3621-3626	tumor	abstract[201]|event[202]|animal|event[204]	giv[201]|giv[202]|giv|new[204]	_	_
24-16	3627-3638	development	abstract[201]|event[202]|event[204]	giv[201]|giv[202]|new[204]	_	_
24-17	3639-3641	in	abstract[201]|event[202]	giv[201]|giv[202]	_	_
24-18	3642-3646	cSCC	abstract[201]|event[202]|substance	giv[201]|giv[202]|giv	coref	24-27
24-19	3647-3648	,	abstract[201]|event[202]	giv[201]|giv[202]	_	_
24-20	3649-3654	which	abstract[201]|event[202]	giv[201]|giv[202]	_	_
24-21	3655-3658	may	abstract[201]|event[202]	giv[201]|giv[202]	_	_
24-22	3659-3666	suggest	abstract[201]|event[202]	giv[201]|giv[202]	_	_
24-23	3667-3672	novel	abstract[201]|event[202]|abstract[207]	giv[201]|giv[202]|new[207]	_	_
24-24	3673-3685	intervention	abstract[201]|event[202]|event|abstract[207]	giv[201]|giv[202]|new|new[207]	_	_
24-25	3686-3693	targets	abstract[201]|event[202]|abstract[207]	giv[201]|giv[202]|new[207]	_	_
24-26	3694-3697	for	abstract[201]|event[202]|abstract[207]	giv[201]|giv[202]|new[207]	_	_
24-27	3698-3702	cSCC	abstract[201]|event[202]|abstract[207]|substance|abstract[209]	giv[201]|giv[202]|new[207]|giv|new[209]	_	_
24-28	3703-3710	therapy	abstract[201]|event[202]|abstract[207]|abstract[209]	giv[201]|giv[202]|new[207]|new[209]	_	_
24-29	3711-3712	.	_	_	_	_
